Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Phase II Study for the Determination of Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of MDS Patients With Favorable Risk Profile.

Next Previous
Trial Profile

Clinical Phase II Study for the Determination of Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of MDS Patients With Favorable Risk Profile.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Valproic acid (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms Valena

Most Recent Events

  • 18 Mar 2015 Biomarkers information updated
  • 21 Aug 2012 Planned end date changed from 1 Mar 2014 to 1 Aug 2013 as reported by ClinicalTrials.gov.
  • 21 Aug 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top